Sandoz launches generic Faslodex
Sandoz has received the Food and Drug Administration’s approval for fulvestrant injection. The product, which is the generic of AstraZeneca’s Faslodex (fulvestrant) injection, is immediately available.
The hormonal therapy medicine is recommended for the three-quarters of women with advanced breast cancer whose tumor expresses the estrogen receptor and slows tumor growth by binding to and blocking the estrogen receptor — a key driver of disease progression.
“Fulvestrant is an important treatment option for women with advanced breast cancer and we will work to help those in the U.S. who need this critical therapy have access to it at an affordable price,” Sandoz president Carol Lynch said. “This treatment fits well with our ongoing strategic focus on oncology, where Sandoz has substantial experience bringing important oncology medicines to hospitals, clinics, doctor’s offices and patients in the U.S.”
Faslodex (fulvestrant injection) had a market value of roughly $541 million for the 12-month period ended March 2019, according to IQVIA.
The hormonal therapy medicine is recommended for the three-quarters of women with advanced breast cancer whose tumor expresses the estrogen receptor and slows tumor growth by binding to and blocking the estrogen receptor — a key driver of disease progression.
“Fulvestrant is an important treatment option for women with advanced breast cancer and we will work to help those in the U.S. who need this critical therapy have access to it at an affordable price,” Sandoz president Carol Lynch said. “This treatment fits well with our ongoing strategic focus on oncology, where Sandoz has substantial experience bringing important oncology medicines to hospitals, clinics, doctor’s offices and patients in the U.S.”
Faslodex (fulvestrant injection) had a market value of roughly $541 million for the 12-month period ended March 2019, according to IQVIA.